Navigation Links
Planning for bacteria in cancer patients may help hospitals fight infections
Date:1/23/2013

What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics. A University of Colorado Cancer Center study published in this month's issue of the International Journal of Infectious Diseases shows the answer: E. coli and Klebsiella pneumoniae are especially prevalent in patients with lung and GI cancers, more so for Klebsiella if these patients have been treated previously with aminopenicillins.

"These are really dangerous infections. You think about Klebsiella it can develop resistance really quickly. And these patients have generally been in and out of hospitals. If you can't treat the infection early, it can quickly become a serious and life threatening condition," says Andrs Felipe Henao-Martnez, MD, clinical fellow in infectious diseases at the CU Cancer Center and University of Colorado Hospital.

His study looked at 462 patients with bacterial blood stream infections who were admitted to hospitals for treatment. Of these patients, 203 had cancer and 259 did not, allowing Henao-Martnez and colleagues to explore the clinical and microbiological differences between these populations. Interestingly, Henao-Martnez could show that most infections existing in cancer patients were acquired in hospital settings and not in the community, while non-cancer patients typically had community-acquired infections.

"Normally every hospital has a spreadsheet, an antibiogram, listing the bacteria and their rate of antibiotic resistance they've found in their patient population. But if you can predict ahead of time what bacteria you're likely to encounter, you can prescribe more targeted antibiotic therapy before infections create complications," Henao-Martnez says.

For example, previous treatment with aminopenicillins, like amoxicillin, and the presence of cancer seemed to significantly increase the likelihood of Klebsiella infection .

"Klebsiella pneumoniae is largely resistant to amoxicillin with the immune system compromised by the cancer and by chemotherapy, and with other bacteria largely wiped away by the amoxicillin class of antibiotics it appears that Klebsiella is left to flourish with little competition in patients with cancer" Henao-Martnez says.

The group recently submitted a paper detailing genetic differences in outcomes in this population of bacterially infected patients admitted for treatment.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Bloomberg School receives $28 million for family planning advocacy
2. Career Planning for Research Bioscientists
3. Virtual plant planning, retrofitting and maintenance
4. SeaSketch, the next generation of UCSBs MarineMap program, will aid marine spatial planning
5. NOAA science supports New Yorks offshore energy planning
6. Study: Odd biochemistry yields lethal bacterial protein
7. Antibacterial agent used in common soaps found in increasing amounts in freshwater lakes
8. Stopping smoking reduces risk of bacterial pneumonia in people with HIV
9. Designer bacteria may lead to better vaccines
10. MBL scientists find bipolar marine bacteria, refuting everything is everywhere idea
11. The saline hiding places for bacteria in Río Tinto could be like those on Mars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW ... therapies for operable and inoperable solid tumor cancers, announced ... Officer of NW Bio, will present at the Phacilitate ... the Hyatt Regency Hotel in Miami, Florida ... session entitled "New Therapeutic Approaches – Expanding the Reach ...
Breaking Biology Technology: